London, United Kingdom
Compass Pathways, founded in 2016, is a United Kingdom-based biotechnology firm on a mission to foster mental well-being. Their slogan, "Our vision is a world of mental wellbeing," encapsulates their commitment to revolutionizing mental health care.
Specializing in Biotechnology, Health Care, Health and Wellness, and Life Sciences, Compass Pathways is at the forefront of innovative treatment methodologies. The company is notably focused on their first clinical development program, the investigational COMP360 psilocybin treatment designed for individuals suffering from treatment-resistant depression.
In a strategic funding round on 16 August 2023, they secured a significant $125.00M Post-IPO Equity investment. This financial injection was led by a consortium of reputable investors including RA Capital Management, Vivo Capital, Laurion Capital, and Logos Capital, among others, underscoring investor confidence in their pioneering approach to mental health solutions.
Anew Era TMS & Psychiatry - Part of Discovery MD
Greenbrook
